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Alphavirus-based vector and replicon systems have been extensively used experimentally and
are likely to be used in human and animal medicine. Whilst marker genes can be inserted easily
under the control of a duplicated subgenomic promoter, these constructs are often genetically
unstable. Here, a novel alphavirus construct is described in which an enhanced green fluorescent
protein (EGFP) marker gene is inserted into the virus replicase open reading frame between nsP3
and nsP4, flanked by nsP2 protease-recognition sites. This construct has correct processing of
the replicase polyprotein, produces viable virus and expresses detectable EGFP fluorescence
upon infection of cultured cells and cells of the mouse brain. In comparison to parental virus,
the marker virus has an approximately 1 h delay in virus RNA and infectious virus production.
Passage of the marker virus in vitro and in vivo demonstrates good genetic stability. Insertion
of different markers into this novel construct has potential for various applications.
Infectious cDNA (icDNA) clones and corresponding
expression vectors have been developed for several alpha-
viruses (Liljestrom & Garoff, 1991; Strauss & Strauss, 1994;
Simpson et al., 1996). In most alphavirus-based expression
vectors, the viral structural genes are replaced by foreign
genes. These vectors are capable of only one round of
infection and are thus non-mobilizable, a property that
has severely hampered their use in studies that require a
spreading, propagating infectious process. Marker and
other recombinant alphaviruses have been produced by
expressing the foreign gene from an internal ribosomal
entry site element or from a duplicated 26S promoter (Raju
& Huang, 1991; Hahn et al., 1992; Pugachev et al., 2000;
Vaha-Koskela et al., 2003). Double-subgenomic vectors
containing marker genes allow direct observation of infec-
tion and have been used successfully in animal experiments
(Levine et al., 1996; Cook & Griffin, 2003). Unfortunately,
these vectors tend to suffer from genome instability, pro-
bably because the inserted genes are introduced as separate
transcription units and have no selective value (Pugachev
et al., 1995, 2000).
An alternative strategy is to insert genes into natural gene
expression units. A marker gene has been inserted success-
fully into the Sindbis virus (SIN) structural gene (Thomas
et al., 2003). SIN genomes with markers inserted into the
non-structural replicase to produce nsP3-fusion proteins
have also been produced (Bick et al., 2003; Frolova et al.,
2006). Production of non-structural–marker fusion pro-
teins has also been successful in other viruses, including
Poliovirus, Hepatitis C virus, Equine arteritis virus and
several filamentous plant viruses (Mueller & Wimmer,
1998; Moradpour et al., 2004; Rajamaki et al., 2005; van
den Born et al., 2005). Here, we report that Semliki Forest
virus (SFV) nsP3–enhanced green fluorescent protein
(EGFP) fusion protein marker virus is viable, but geneti-
cally unstable; however, by the novel strategy of placing the
EGFP insert between nsP3 and nsP4 flanked by duplica-
tions of the nsP3/4 nsP2 protease-recognition site, we have
generated a viable, genetically stable virus with only minor
changes in phenotype.
An SFV nsP3–EGFP fusion protein virus was engineered
by subcloning and PCR-based mutagenesis. The C residue
at position 5447 of pSFV4 (Liljestrom et al., 1991) was
changed to G and a 12 bp long sequence, GGGCCCAT-
AGGATCC, was inserted after the modified codon. The
resulting construct was designated pSFV(3F)4. The sequ-
ence encoding EGFP was PCR-amplified, cloned into
pSFV(3F)4 and the resulting icDNA clone was designated
pSFV(3F)4-EGFP (Fig. 1a). Infectious virus, SFV(3F)4-
EGFP, was obtained by electroporation of capped in vitro3These authors contributed equally to this work.
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transcripts as described by Liljestrom et al. (1991). The
primary virus stocks (P1) were collected after 24 h, titrated
and used to infect fresh BHK-21 cells (m.o.i., 0.1). The
second-passage stocks (P2) were also harvested at 24 h.
SFV(3F)4-EGFP virus was viable and expressed the
expected nsP3–EGFP fusion protein (Fig. 2a). However,
plaque purification followed by analysis of the fluorescence
produced by individual plaques and Western blotting
demonstrated that this virus was genetically unstable; a
truncated form of the nsP3–EGFP fusion protein was
present even in cells transfected directly with in vitro-
synthesized RNA. The genetic instability of this virus is
most probably due to defect(s) in the formation or func-
tioning of replication complexes. As with SIN nsP3-fusion
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Fig. 1. (a) Schematic representation of recombinant SFV genomes. The sequences of the inserted High (H) site and the native
nsP3/4 nsP2 cleavage sites are shown. The 30 aa sequence from the C terminus of the nsP3 (aa 453–482), which was fused
to the C terminus of EGFP, is indicated. The nsP2 protease-cleavage sites are indicated by Q. Numbers indicate positions of
amino acid residues in nsP3; (6) indicates the sequence IFSSDT (from nsP4). (b) Growth of SFV4 and SFV(3H)4-EGFP in
BHK-21 cells infected with P2 viruses. (c) Localization of EGFP and nsP3 in BHK-21 cells infected with SFV(3F)4-EGFP. (d)
Localization of EGFP and nsP3 in BHK-21 cells infected with SFV(3H)4-EGFP. In both (c) and (d), cells infected at an m.o.i. of
1 were fixed at 5 h post-infection. EGFP was detected by its fluorescence, and nsP3 with a polyclonal antibody and a
secondary antibody conjugated to Texas red. (e) Virus-infected EGFP-positive cells (green) in mouse brain 2 days post-
inoculation, detected by confocal microscopy; p denotes the hippocampal pyramidal cell layer and c the cortex. Bar, 100 mm.
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constructs (Ryman et al., 2005; Frolova et al., 2006;
Ventoso et al., 2006), SFV(3F)4-EGFP and its analogues
may have uses to study replicase gene expression, replicase
protein localization and interactions, but its instability
precludes application in in vivo pathogenesis studies.
In a novel strategy, a second virus was engineered in which
EGFP was placed between nsP3 and nsP4 flanked by nsP2
cleavage sites. Starting with pSFV(3F)4-EGFP, the C
terminus of nsP3 was restored and an nsP2 protease-
recognition site was added between nsP3 and EGFP
(Fig. 1a). The inserted protease-recognition sequence was
based on the nsP3/4 junctional sequence, which is cleaved
with high efficiency (Merits et al., 2001; Vasiljeva et al.,
2001). The first amino acid residue after the inserted
cleavage point was also changed from Tyr to Gly; nsP2
prefers Gly in the P19 position and Gly represents a
stabilizing amino acid (Lulla et al., 2006; Varshavsky,
1996). The P19 Gly was followed by aa 2–7 from the N
terminus of nsP4 (Fig. 1a). The region encoding the C
terminus of nsP3 with indicated downstream sequence
was created by PCR amplification and cloned into
pSFV(3F)4-EGFP. The resulting clone and virus were
designated pSFV(3H)4-EGFP and SFV(3H)4-EGFP,
respectively (Fig. 1a).
Infectious-centre assays (Gorchakov et al., 2004) demon-
strated that 3.16105 to 4.46105 plaques (mg transfected
RNA)21 were obtained for both pSFV(3H)4-EGFP and
pSFV4 transcripts, with no statistically significant differ-
ence between them. In one-step growth studies (m.o.i., 20),
relative to SFV4, production of infectious SFV(3H)4-EGFP
was delayed by approximately 1 h (Fig. 1b). However, as
SFV(3H)4-EGFP was able to replicate to 109 p.f.u. ml21
within 10 h, it can be concluded that insertion of EGFP
between nsP3 and nsP4 did not affect virus replication
substantially.
To determine whether the EGFP insertion in SFV(3H)4-
EGFP was inherited stably, 96 virus plaques were purified
from each of five in vitro passages (P1–P5) in BHK-21 cells
(m.o.i., 0.1) and each of five in vivo passages (M1–M5) in
mouse brains. After each passage, the percentage of viruses
expressing EGFP was assessed by random selection of 96
plaques followed by determination of EGFP expression. All
plaques from the P2 stock of SFV(3H)4-EGFP were EGFP-
positive and .90 % were EGFP-positive after the fifth
passage. Even greater stability was observed for in vivo-
propagated stocks: after the fifth passage, only one plaque
(1/96) was EGFP-negative. As an EGFP-negative phenotype
could result from EGFP inactivation by point mutation or by
deletion, we RT-PCR-amplified and sequenced the corre-
sponding regions for several of the EGFP-negative (in vitro-
passaged) plaque-purified viruses. In all cases, these genomes
contained large in-frame deletions, indicating that deletions
in the marker gene do occur upon passage of SFV(3H)4-
EGFP. Whilst the frequency of this process may be low, given
their growth advantage, deleted genomes are likely to
increase in the viral population following multiple passages.
In SFV-infected cells, nsP3 is known to associate with
modified endosomes and lysosomes (Froshauer et al.,
1988). In contrast, free EGFP is typically localized diffusely
in the cytoplasm and more abundantly in the nucleus. In
SFV(3F)4-EGFP-infected BHK-21 cells, EGFP co-localized
with nsP3 to punctate cytoplasmic structures, presumably
virus replicase complexes (Fig. 1c). In contrast, SFV(3H)4-
EGFP-infected cells showed granular cytoplasmic staining
for nsP3 and diffuse, predominantly nuclear staining for
EGFP (Fig. 1d). The independent localization of nsP3 and
EGFP in the SFV(3H)4-EGFP-infected cells indicates that
EGFP was released from the replication complexes.
To determine the phenotype of SFV(3H)4-EGFP in vivo,
groups of six 5–6-week-old female BALB/c mice were
inoculated (20 ml) intracerebrally with SFV4(3H)-EGFP or
SFV4. All animal experiments were carried out under the
authority of a UK Home Office licence and were approved
by the University of Edinburgh ethical-review process.
Mice in both groups had clinical signs of encephalitis at day
2 and were sampled. Half brains were fixed in 4 % neutral-
buffered formalin for 16 h, processed through graded
sucrose solutions, frozen in OCT and cut into sections
(12 mm). EGFP-positive cells were observed readily in all
(n56) brains infected with SFV(3H)4-EGFP (Fig. 1e).
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Fig. 2. (a) Expression of EGFP and viral ns proteins by
recombinant viruses. BHK-21 cells were infected (m.o.i., 20) with
SFV4 (wt), P2 stock of SFV(3H)4-EGFP (H) or P1 stock of
SFV(3F)4-EGFP (F), or were mock-infected (M), and cell lysates
were analysed by Western blotting. The antibody used for
detection is indicated at the top of each panel. Specific signals
for nsP1, nsP2, nsP3, nsP4 or EGFP are indicated with a solid
arrow; bands corresponding to nsP3–EGFP and EGFP–nsP4
fusion proteins are marked with an open arrow. (b) Proteins
synthesized in infected cells were labelled metabolically at 3 h
post-infection and chased for 1, 3, 8 or 24 h. Cell lysates were
immunoprecipitated with anti-nsP1, anti-nsP3 or anti-EGFP
antibodies and analysed by SDS-PAGE.
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Titration of the other half brain, as described previously
(Fazakerley et al., 1993), demonstrated titres of infectious
virus ranging from 16109 to 36109 p.f.u. g21, with no
difference between mice infected with SFV(3H)4-EGFP
and those infected with parental SFV4. We conclude that,
as with SFV4, SFV(3H)4-EGFP is neurovirulent and can
replicate and spread efficiently in the mouse brain and that
SFV(3H)4-EGFP-infected brain cells express sufficient
EGFP to be observed readily by fluorescence microscopy.
Expression of the ns proteins in SFV(3H)4-EGFP- and
SFV(3F)4-EGFP-infected BHK-21 cells was examined by
Western blotting (Fig. 2a). At 6 h post-infection, cells were
lysed in Laemmli buffer and samples corresponding to
100 000 cells were separated by SDS-PAGE. Monospecific
rabbit polyclonal antibodies were used to detect nsP1, nsP3
and nsP4, and a mouse monoclonal antibody was used to
detect nsP2 (Pera¨nen et al., 1988; Laakkonen et al., 1994;
Rikkonen et al., 1994; Kujala et al., 1997). Individual nsP1,
nsP2, nsP3, nsP4 and EGFP were observed readily in
SFV(3H)4-EGFP-infected cells. No nsP3–EGFP fusion pro-
tein was detected, but a small amount of unprocessed EGFP–
nsP4 was detected by antibodies to both nsP4 and EGFP. In
SFV(3F)4-EGFP-infected cells, nsP3 was, as expected, present
predominantly as an nsP3–EGFP fusion protein. A small
amount of free nsP3 was also present; this may have resulted
from the rapid generation of EGFP-negative genomes.
To study the dynamics of cleavage of the SFV(3H)4-
EGFP polyprotein, infected cells (m.o.i., 100) were pulse
labelled metabolically for 15 min with 50 mCi (1.85 MBq)
[35S]methionine and [35S]cysteine, and nsP3 and its
precursors were immunoprecipitated with antiserum
against nsP3 and Protein A–Sepharose. Immunocomplexes
were separated by SDS-PAGE and radiolabelled proteins
were visualized by autoradiography. In pulse-labelled cells,
the P123–EGFP, P3–EGFP–4 and P3–EGFP processing
intermediates were all detected, whereas in chased
samples, processing intermediates were not detected or
were present in lower quantities, and the amount of fully
processed nsP3 was increased (data not shown). Thus, all
expected processing products, except the very rapidly
processed P123–EGFP–4, were detected and no apparent
disturbance of processing was observed.
In BHK-21 cells, EGFP is generally quite stable, with an
estimated half-life of 24 h. However, in BHK-21 cells
infected with SFV(3H)4-EGFP, the EGFP signal detected
late in infection by fluorescence microscopy had decreased
considerably, suggesting low EGFP stability. To assess the
stability of the EGFP and ns proteins, BHK-21 cells infected
with SFV(3H)4-EGFP or SFV4 were labelled metabolically,
chased and EGFP, nsP1 and nsP3 were immunoprecipi-
tated. For both viruses, only a small decrease in nsP1 and
nsP3 was detected over 24 h (Fig. 2b). In contrast, by 24 h,
the amount of EGFP was below the detection limit of this
analysis (Fig. 2b). Thus, the low amounts of EGFP
observed by microscopy indeed represent rapid degrada-
tion of EGFP. The processed EGFP has a Gly residue at its
N terminus that, according the N-end rule, is stabilizing.
Most likely, EGFP instability results from the duplicated
C-terminal sequence of nsP3 (Fig. 1a), which, as a result
of the construction strategy, remains attached to the C
terminus of EGFP. If this is the case, then the effect of this
same sequence in its native location (C terminus of nsP3)
is either different or is suppressed by interaction(s) with
other components of the replicase complex.
Virus RNA synthesis by SFV4 and SFV(3H)4-EGFP was
compared by [3H]uridine labelling. Relative to SFV4-infected
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Fig. 3. (a) Synthesis of virus RNA. BHK-21 cells were infected with SFV4 or SFV(3H)4-EGFP; at 1 h post-infection,
actinomycin D (2 mg ml”1) and, at 2 h, 25 mCi (0.925 MBq) [3H]uridine, were added. Cells were collected at 3, 4, 5, 6, 7 and 8 h
post-infection. Total RNA was precipitated by trichloroacetic acid. Incorporated radioactivity was measured by liquid
scintillation. Each bar represents the mean of six replicates; error bars indicate SD. (b) Shutdown of cellular translation in BHK-
21 cells infected with SFV4 or SFV(3H)4-EGFP. Proteins synthesized in infected cells were labelled metabolically at 1 h
intervals and cell lysates were analysed by SDS-PAGE. M, Mock-infected cells.
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cells, SFV(3H)4-EGFP-infected cells had a delay in virus
RNA synthesis (Fig. 3a); this was most obvious at 3–5 h
post-infection and less so at later time points. To analyse
whether insertion of the marker gene altered the temporal
expression of SFV structural proteins or the shutdown of
host-cell translation, protein synthesis in infected BHK-21
cells was studied by metabolic labelling. As observed with
virus growth (Fig. 1b) and RNA synthesis (Fig. 3a), pro-
duction of viral proteins C, E1 and p62 in SFV(3H)4-
EGFP-infected cells started approximately 1 h later than
in SFV4-infected cells. A longer, approximately 2 h, delay
was observed for host-cell translational shutdown (Fig. 3b).
In all measurements of virus replication and growth,
SFV(3H)4-EGFP was slightly slower than SFV4. The possi-
ble reasons for this include effects resulting from larger ns
polyprotein sizes and delays or defects in replicase-complex
formation. However, these changes are unlikely to preclude
use of this virus, as it replicates to high titres and remains
neurovirulent. Despite the small duplication of viral sequ-
ence necessitated by the addition of the nsP2 processing
site upstream of EGFP, SFV(3H)4-EGFP demonstrated
remarkably improved genetic stability relative to SFV(3F)4-
EGFP. However, it should be noted that, at late passages
in vitro, some genomes with a deletion in the marker gene
were present. Attempts to reduce this by removing the
duplicated 6 aa from the N terminus of EGFP, or by
decreasing the length of the nsP3 C-terminal fragment
fused to the C terminus of EGFP, resulted in viable
viruses, but did not increase their genetic stability (data
not shown). Importantly, following replication and spread
of SFV(3H)4-EGFP in the mouse brain, no deletion
variants were observed until passage M5, demonstrating
the utility of this virus for in vivo pathogenesis studies.
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